Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 8 5 PH6 versus AMINOSYN II 3 5 M IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 8 5 PH6 versus AMINOSYN II 3 5 M IN DEXTROSE 5 IN PLASTIC CONTAINER.
AMINOSYN 8.5% (PH6) vs AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 8.5% (pH 6) provides a mixture of essential and nonessential amino acids for protein synthesis and nitrogen balance maintenance in patients unable to tolerate oral or enteral nutrition.
Aminogen II 3.5% M in Dextrose 5% provides essential and non-essential amino acids and dextrose for parenteral nutrition. Amino acids are utilized for protein synthesis and metabolic processes. Dextrose provides a source of calories and energy.
1-1.5 g amino acids/kg/day intravenously, typically 500 mL of a 8.5% solution (42.5 g amino acids) infused over 8-24 hours.
Aminosin II 3.5% M in Dextrose 5% is administered intravenously. Typical adult dose is 1-2 L per day, providing 35-70 g amino acids and 50-100 g dextrose per day, infused at a rate of 0.5-1.5 mL/kg/hour.
None Documented
None Documented
Not applicable as a fixed value; elimination half-life of individual amino acids varies (minutes to hours) and is dependent on metabolic demand and renal function.
Amino acids have variable elimination half-lives (e.g., 0.5-6 h) depending on individual amino acid; dextrose half-life ~1-2 h. Clinical context: Used for continuous infusion, not bolus.
Primarily renal; elimination depends on metabolic utilization. Unused amino acids are deaminated and excreted as urea in urine (over 90%). Fecal elimination is negligible.
Amino acids are primarily metabolized, with nitrogen excreted as urea (renal, ~80-90%) and ammonia; minimal fecal excretion. Dextrose is fully metabolized to CO2 and water.
Category C
Category C
Amino Acid Solution
Amino Acid Solution